Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
Personalis (Nasdaq: PSNL), a company specializing in advanced genomics for precision oncology, has announced its management team's upcoming participation in the TD Cowen's 45th Annual Health Care Conference. The event is scheduled to take place on Monday, March 3, 2025, and will be held at the Boston Marriott Copley Place in Boston, MA.
Personalis (Nasdaq: PSNL), un'azienda specializzata in genomica avanzata per l'oncologia di precisione, ha annunciato la partecipazione del suo team di gestione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. L'evento si svolgerà lunedì 3 marzo 2025 presso il Boston Marriott Copley Place a Boston, MA.
Personalis (Nasdaq: PSNL), una empresa especializada en genómica avanzada para la oncología de precisión, ha anunciado la próxima participación de su equipo directivo en la 45ª Conferencia Anual de Salud de TD Cowen. El evento está programado para el lunes 3 de marzo de 2025 y se llevará a cabo en el Boston Marriott Copley Place en Boston, MA.
Personalis (Nasdaq: PSNL), 정밀 종양학을 위한 고급 유전체학을 전문으로 하는 회사가 TD Cowen 제45회 연례 건강 관리 회의에 경영진 팀의 참여를 발표했습니다. 이 행사는 2025년 3월 3일 월요일에 보스턴 MA의 보스턴 메리어트 코플리 플레이스에서 개최될 예정입니다.
Personalis (Nasdaq: PSNL), une entreprise spécialisée dans la génomique avancée pour l'oncologie de précision, a annoncé la prochaine participation de son équipe de direction à la 45e Conférence Annuelle sur la Santé de TD Cowen. L'événement est prévu pour le lundi 3 mars 2025 et se tiendra au Boston Marriott Copley Place à Boston, MA.
Personalis (Nasdaq: PSNL), ein Unternehmen, das auf fortgeschrittene Genomik für präzise Onkologie spezialisiert ist, hat die bevorstehende Teilnahme seines Management-Teams an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Die Veranstaltung findet am Montag, den 3. März 2025 im Boston Marriott Copley Place in Boston, MA statt.
- None.
- None.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218667216/en/
Investors:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Source: Personalis, Inc.
FAQ
When is Personalis (PSNL) presenting at TD Cowen's Health Care Conference 2025?
Where will the TD Cowen Health Care Conference featuring Personalis (PSNL) be held?
What type of company is Personalis (PSNL)?
Will Personalis (PSNL) management team attend TD Cowen's 2025 Healthcare Conference?
